Background and aims Methamphetamine use is increasingly prevalent and associated with HIV transmission.
INTRODUCTION
Methamphetamine continues to dominate the synthetic drug market globally, with increasing use in Europe and North America [1] . There were at least 569 000 current methamphetamine users in the United States in 2014 [2] , with increasing prevalence in several regions [3] . Methamphetamine use among men who have sex with men (MSM) is prevalent, and associated with significant medical and social risks [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In 2014, 13% of MSM in San Francisco reported current methamphetamine use [16] . MSM accounted for 70% of newly diagnosed HIV infections in 2014 [17] [18] [19] and multiple studies have demonstrated an independent association between methamphetamine use and risk behaviors among MSM, including high-risk injection [14] , condomless anal intercourse [20] [21] [22] [23] , multiple partners [20, 24] , increased duration of sex [25] , having anonymous partners, having sex in a public sex venue, meeting partners in a bathhouse and exchanging money or drugs for sex [20] [21] [22] [23] [24] [25] .
There are no pharmacotherapies approved for treatment of methamphetamine use disorder [26, 27] . Naltrexone, a μ-opioid receptor antagonist approved for alcohol and opioid use disorder treatment, showed promise in reducing amphetamine relapse among dependent, currently abstinent, heterosexuals [28] . Administration of naltrexone also led to reductions in subjective effects of amphetamine in laboratory studies [29] [30] [31] [32] , although another study found no effect on reinforcing effects [33] . Methamphetamine, metabolized rapidly into amphetamine, enhances release of mRNA precursors for endogenous opioids that activate μ-opioid receptors and consequently levels of extracellular dopamine [34] [35] [36] . Hence, naltrexone was believed to attenuate downstream dopamine release by preventing methamphetamineinducible endogenous opioids from activating μ-opioid receptors, tempering the reinforcing effects of methamphetamine [36, 37] . Naltrexone has also been associated with a reduction in urge-driven problematic disorders, suggesting potential benefit in HIV risk behaviors [38] [39] [40] [41] [42] [43] [44] .
METHODS
To test the hypotheses that naltrexone would reduce methamphetamine use and sexual risk behaviors, we conducted a double-blind, placebo-controlled, randomized trial of monthly injections of extended-release naltrexone (XRNTX, VIVITROL ® ) among 100 methamphetaminedependent MSM at the San Francisco Department of Public Health from 2012 to 2015. The aims were to determine if XRNTX, compared to placebo, reduced (1) methamphetamine use and (2) sexual risk behaviors. Study procedures were approved by the University of California, San Francisco Institutional Review Board (IRB no. 11-06276).
Recruitment
Potential participants were recruited from clinics, community-based organizations, nightlife venues, websites, snowball referrals and recruitment flyers. Interested individuals were administered a questionnaire by telephone to establish preliminary eligibility and schedule in-person screening. At screening participants gave informed consent and were evaluated for eligibility, including being aged 18-65 years; methamphetamine-dependent by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV-TR (SCID) [45] ; interested in reducing or stopping methamphetamine use; born male or female and not identifying as female; reporting anal sex with men while under the influence of methamphetamine within prior 6 months; being methamphetamine metabolite-positive by urine; and, for HIV-infected individuals, having a CD4 count > 200 cells/mm 3 or a CD4 count 100-199 cells/mm 3 and HIV viral load < 200 copies/ml. Exclusion criteria included any psychiatric condition (e.g. psychosis or suicidality) that in the investigator's judgment precluded safe participation; current use of or urine positive for opioids or a known medical condition likely to require opioid analgesics; current alcohol dependence by SCID; alanine or aspartate aminotransferase ≥ 5 times upper limit of normal; estimated glomerular filtration rate < 50 ml/min; thrombocytopenia or coagulation disorder; known intolerance or hypersensitivity to naltrexone or other study drug components; acute illnesses requiring prolonged medical care or chronic illnesses likely to progress clinically during participation; pending legal proceedings with high risk for incarceration; participating in another study; and any condition that, in the investigator's judgment, would interfere with safe participation or adherence to procedures.
Procedures
Two screening visits assessing for eligibility included physical examination; medical history; mental health and substance use history by SCID; qualitative urine testing for methamphetamine and other substances with MedTox EZ-SCREEN ® ; blood count, comprehensive metabolic panel and, for participants born female, pregnancy testing. For otherwise eligible participants testing positive for opioids, a naloxone challenge was administered prior to study drug administration to ensure no risk for opioid withdrawal. Participants who reported being HIV or hepatitis C virus (HCV)-negative or unknown were given an OraQuick ADVANCE ® Rapid HIV-1/2 test or OraQuick ® HCV Rapid Antibody Test, respectively, and pooled HIV viral load testing using the Abbott Realtime HIV-1 assay; participants found newly HIV-positive during screening were referred to care and enrollment deferred for 3 months. HIV-positive participants had CD4 and viral load testing. All participants received HIV risk reduction counseling. Two additional 'run-in visits' before enrollment included urine sample collection and assessed participants' ability to adhere to study schedule. At enrollment, the 1 : 1 random allocation sequence was generated from a SAS macro program using randomly-selected block sizes (of two or four) to ensure balanced study arms by the study biostatistician. Only the off-site biostatistician and pharmacist knew allocation assignments. Following enrollment, participants were seen weekly to provide urine for methamphetamine and other substance testing and received 30-minute substance use counseling delivered by staff trained on a manual-driven psychosocial treatment program using cognitive behavioral therapy [46] and motivational interviewing techniques [47] [48] [49] . Study drug was administered by gluteal injection by study clinicians at enrollment and 4-and 8-week visits. Blood count and comprehensive metabolic panel were performed at 4, 8 and 12-week visits, as were physical examinations and pregnancy tests, as needed. HIV risk-reduction counseling and testing and HCV testing were repeated for HIV-and HCV-negative participants at 12-week visits. Participants were reimbursed $10 for the first screening visit, $25 for the second and $10 for each run-in; $50 for enrollment and weeks 4, 8 and 12, and $15 for other weekly visits. Research staff made reminder calls and/or texts prior to study visit appointments.
The study drug, XR-NTX 380 mg and matched placebo, was prepared by an off-site pharmacist in identical-looking vials to maintain double-blind for staff and participants. Clinicians reconstituted and administered study drug from vials numbered to correspond with the treatment allocation sequence. Participants remained on-site for at least 30 minutes after injections to assess for adverse reactions.
If participants opted into genetic testing, a small blood sample was collected at enrollment and stored until enrollment was complete, then tested at the Clinical and Toxicology Research Laboratory of San Francisco General Hospital to determine the presence of the A118G single-nucleotide polymorphism (SNP) thought to be relevant to mediation of XRNTX effects in the opioid receptor μ1 (OPRM1) [50] . Genomic DNA was extracted from peripheral blood cells (QIAamp DNA Blood Kit; Qiagen Inc., Valencia, CA, USA). After polymerase chain reaction, A118G genotype was determined with a Taqman 5 0 nuclease assay, using allele specific probes (Taqman SNP Genotyping Assay, Catalog no. C8950074; Applied Biosystems, Foster City, CA, USA) under the protocol provided with the kit. Three known controls (determined by next-generation sequencing) were used for each genotype. All testing was performed on the Rotor-Gene Q real time PCR system (Qiagen Inc.).
Measures
Primary outcome was the overall level (2-12 weeks) and change in level of the proportion of methamphetaminepositive urines; all results were confirmed by two staff. Secondary outcomes were sexual HIV risk behaviors, including number of male partners, number of male partners with whom meth was used, episodes of anal sex with serodiscordant partners, episodes of unprotected anal sex with serodiscordant partners, episodes of insertive unprotected anal sex with serodiscordant partners, episodes of receptive unprotected anal sex with serodiscordant partners, study injections administered and adverse events classified by standard criteria [51] . Audio-computer assisted self-interviews (ACASIs), were completed by participants weekly, addressing recent substance use and cravings [52, 53] . At enrollment and weeks 4, 8 and 12, additional questions assessed substance use treatment, Severity of Dependence (SDS) and sexual risk behaviors [54] [55] [56] . We assessed for depressive symptoms with the Center for Epidemiologic Studies Depression scale [57] and screened for psychological distress with the Patient Health Questionnaire-2 (PHQ-2).
Data analysis
Our sample of 100 participants provided 80% power to detect 19-25% change in level of positive urines among participants in the XRNTX group, relative to placebo [58] . Primary outcome data were analyzed by intentionto-treat, without regard to adherence (i.e. all participants were included in efficacy analyses), using a generalized estimating equations (GEE) model with robust standard errors to account for within-participant clustering of binary responses. To obtain direct estimates of risk ratios (RRs), log-link models were used. The form of the model, which omits week 1 (first post-enrollment visit) results, was pre-specified, based on the a priori hypothesis that XRNTX would have gradually increasing efficacy after a short initial delay to achieve steady state levels. The analysis compared trends in urine-positivity from baseline to week 12 modeled as group-specific linear functions of time since randomization. Treatment effect was captured by the divergence of XRNTX and placebo trends at 12 weeks, net of the fitted baseline difference, and was assessed using a test for the time × treatment interaction. Use of robust standard errors allowed us to account for within-subject correlation of the responses without making parametric assumptions. The fit of the model was assessed informally by plotting the group-specific fitted trends along with raw percentages. Additionally, we tested the difference in parallel trajectories between 2 and 12 weeks with a model without the interaction term between treatment and time, to estimate the main overall effect of treatment. Five sensitivity analyses were conducted: (1) including week 1 results; (2) imputing a positive result for all missing urine samples; (3) adjusting for imbalanced baseline characteristics with P < 0.10 and baseline correlates of missing or positive urine samples; (4) including participants who completed final visits beyond the maximum allowable visit window; and (5) stratifying participants by intensity of methamphetamine use at baseline. All available data were included in each analysis.
In addition, we conducted an as-treated analysis, focusing on the effect of cumulative dose, calculated as the number of study injections received, as a time-dependent covariate. In this analysis, we controlled for the placebo effects of adherence, estimating the as-treated effect by the interaction between arm and cumulative study injections received. We also determined whether treatment effect was modified by μ-opioid receptor (OPRM1) gene polymorphisms in models that stratified by genotype result.
Finally, to evaluate for consecutive weeks of continued abstinence, we compared the 'number of beyond-threshold weeks of success' (NOBWOS), using the Wilcoxon test [59] .
We used linear, logistic and negative binomial GEE models to assess treatment effects on secondary outcomes, including CES-D scores and sexual risk behaviors. Acceptability of XRNTX was evaluated as the percentage of study injections completed by arm using the Wilcoxon test. To assess safety, we compared frequency of adverse events of various types by arm using the two-tailed Fisher's exact test. Finally, to evaluate non-significant findings, we calculated Bayes factor [60] using R (R Foundation for Statistical Computing, Vienna, Austria) [61] .
RESULTS

Subjects
Target sample was achieved and data collected from September 2012 to September 2015. Figure 1 shows results for screening, study arm assignment and retention; 194 participants provided written informed consent for screening. The most common reasons for ineligibility were: not methamphetamine-dependent by SCID (n = 15), psychotic disorder [11] , exclusionary laboratory results (n = 8) or a medical condition precluding safe participation by clinical judgment (n = 8). Two participants were excluded due to current alcohol dependence.
Participant characteristics were similar in both arms (Table 1) , with the exception of: (1) methamphetamine use through rectal administration was reported by a greater proportion of XRNTX participants compared to placebo (52 versus 16%; P < 0.01) and (2) using methamphetamine during sex greater than 50% of the time was more common in the XRNTX arm (80 versus 46%; P < 0.01).
Study retention and adherence
The mean weekly visit completion rate was 90% [standard deviation (SD) = 0.19]. Weekly retention was similar among XRNTX and placebo arms [91% (0.17) versus 89% (0.21); P = 0.42]. There were no significant differences in trial completion by arm [XRNTX 94% (n = 47), placebo 92% (n = 46); P ≥ 0.99]. Four participants dropped out after randomization (two in each arm). Two additional participants came for their final visit 16 and 34 days past scheduled final visits, outside the maximum allowable window, and were excluded from primary analyses.
Participants received 94.0% of study drug injections (282 of 300; XRNTX 96.7%; placebo 91.3%; P = 0.09). Of monthly follow-up visits, 94% (282 of 300) were completed [XRNTX 95% (143 visits), placebo 93% (139 visits); P = 0.87]. Mean number of urine samples collected was 10.5 (XRNTX 10.7, placebo 10.3; P = 0.36); Fig. 2 shows the numbers of participants in each group providing urine samples by week. Participants completed 91% of ACASI surveys (329 of 360; XRNTX 98%, placebo 95%; P = 0.201) and 83% of weekly substance use counseling sessions (911 of 1100; XRNTX 85%, placebo 81%; P = 0.06).
When asked to guess treatment assignment at study completion, participants showed no evidence of unblinding: 21 (42%) XRNTX and 16 (32%) placebo participants guessed correctly (P = 0.40).
Outcomes
Methamphetamine use
During four pre-enrollment visits, the median number of methamphetamine metabolite-positive urines among enrollees was 3 [interquartile ratio (IQR) = 2-4]. At baseline, 75 (75%) participants had positive urines [38 (76%) XRNTX, 37 (74%) placebo; P = 0.81]. The proportion of Figure 1 Enrollment and retention by treatment arm positive urines at baseline to month 3 decreased in both arms, from 78 to 70% in XRNTX and 74 to 64% in placebo participants (Table 2 The placebo urine positivity rate (observed 74%; expected 70-90%) and missing urine sample rates (observed 12%; expected 17%) were within parameters assumed in sample size calculations, although within-subject correlation of urines (observed 38%; expected 50-90%) was lower than assumed. Using observed parameters, the updated minimum detectable net percentage reduction in urine positivity was at the upper range of a priori estimates. Based on the 19-25% urine positivity rate reductions that the study had 80% power to detect as the theoretical effect of XRNTX on this outcome, we obtained Bayes factors of 0.13-0.29, depending on how the theoretical effect was specified, all below the guideline threshold of 0.3 to establish a null effect.
Sensitivity analyses
There was no significant effect observed in favor of XRNTX in sensitivity analyses after including week 1 urine results Table 2 Weekly methamphetamine urine-positivity rates by treatment arm and overall treatment effect on urine positivity. 50 (74) 45 (76) 45 (67) 45 (60) 43 (58) 41 (66) 41 (66) 41 (68) 40 (60) 40 (73) 40 (70) 45 ( 49 (78) 45 (82) 46 (87) 46 (72) 46 (63) 43 (74) 44 (75) 42 (76) 43 (65) 41 (73) 41 (78) 47 ( 
Sexual risk behaviors
Baseline frequency of sexual risk behaviors and subsequent decline were similar in XRNTX and placebo arms, demonstrating no effect of XRNTX over placebo (Table 3) .
Medication adherence
Participants received a mean of 2.8 (SD = 0.5) study injections, with no difference by arm [XRNTX 2.9 (0.3), placebo 2.7 (0.6); P = 0.21]. Ninety per cent of XRNTX participants received all three study injections, compared to 82% of placebo participants (P = 0.2).
As-treated analysis
In the as-treated analysis, the effect of treatment on methamphetamine positivity rate for a greater number of cumulative study injections received was not significantly different by arm (β coefficient = À0.015, 95% CI = -0.08 to 0.05, P = 0.66). The effect of receiving an injection in past month on monthly methamphetamine positivity rate was not significantly different between arms (β-coefficient = À0.036, 95% CI = -0.27 to 0.20, P = 0.76).
Treatment effect by OPRM1 A118G single-nucleotide polymorphisms
Seventy-two participants agreed to be genotyped, 26 of whom had heterozygous and 46 homozygous (wild-type) genotype (see Table 1 for the distribution of genotypes by arm). There was no significant effect stratifying by OPRM1 A118G genotype; effect of treatment over time had a P-value of 0.64 and 0.97 for participants with heterozygous and homozygous genotype, respectively.
Safety
There were no differences in frequency of adverse events between arms (P ≥ 0.99). There were three serious adverse events during this study, none of which were deemed related to study drug. Two placebo arm participants were hospitalized, one for left facial drooping and hearing loss in the context of syphilis and the other for gammahydroxybutyric acid overdose. One XRNTX arm participant, who had not received study medication, was hospitalized for self-injurious behavior.
The most common adverse events reported in both arms were: injection site pain [24 (48%) No XRNTX participants declined study drug due to adverse events; three placebo participants declined study injections (0 versus 6%; P = 0.24) due to injection site pain or nausea from prior study injections.
DISCUSSION
We found no effect of XRNTX on methamphetamine use, methamphetamine craving or sexual risk behaviors among dependent, actively using MSM when compared to placebo. This result is supported by Bayes factor analysis, which observed values below the guideline threshold to establish a null effect, suggesting that this medication alone is unlikely to provide a clinically meaningful benefit in this population. There were no serious adverse events related to study drug and no difference in the frequency of adverse events by study arm.
These findings are aligned with those of many other negative trials of pharmacotherapies for methamphetamine use disorder [62] . Notwithstanding favorable preclinical data for many medications, most fail phase II trials. There are few exceptions to this trend, with mixed data for medications such as methylphenidate [63] and bupropion [64] , and some early promise for mirtazapine, which is active in multiple neurotransmitter systems [65] . Similar challenges have affected development of pharmacological treatments for cocaine use disorder, suggesting that treating stimulant use may require targeting multiple neurotransmitter systems simultaneously with a combination of agents.
Our study resulted in remarkably high medication adherence for a study of methamphetamine use. Medication adherence among methamphetamine-dependent individuals is poor in most trials [65] [66] [67] , yet was higher in this study even than in other trials utilizing XRNTX [68] [69] [70] . Our approach to administering the injection may have differed somewhat from other clinicians: first, aiming to reduce the common problem of clogged syringes, after drawing up study drug we left the syringe barrel slightly inverted to avoid precipitation toward the needle, and we attached the needle only immediately before injection. Secondly, we administered study drug into the ventrogluteal site, whereas many clinicians may utilize the prior standard dorsogluteal site which has more pain receptors, nearby nerve bundles and thicker fat. Infrequent needle clogging and less painful injections may have contributed to adherence.
Our study has limitations. First, our sample was MSM, most of whom had positive HIV serostatus, and results may not be generalizable to other populations. Furthermore, our participants were actively using methamphetamine, in contrast to an earlier trial of relapse prevention among amphetamine-dependent people [28] . Secondly, we studied XRNTX in isolation, whereas there may be benefit when the medication is combined with other agents [71] .
In summary, notwithstanding excellent medication adherence, we found no evidence that XRNTX alone supports reduced methamphetamine use among methamphetaminedependent, actively using MSM when compared to placebo. The remarkable level of adherence, however, should promote further research into long-acting medications to treat methamphetamine and other substance use disorders. 
